H.C. Wainwright analyst Edward White says TG Therapeutics’ just approved Briumvi is the lowest-priced, branded disease modifying therapy approved in multiple sclerosis. The annual wholesale acquisition cost for Briumvi is $59,000 compared to $71,187 for Ocrevus, White tells investors in a research note titled "Briumvi Priced For Success." The analyst believes Briumvi’s "faster infusion time and lower price could enable it to quickly gain share." He estimates sales of $46.1M in 2023 for Briumvi in multiple sclerosis, growing to $558.8M in 2028. White keeps a Buy rating on TG Therapeutics with a $24 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- Another Big Day for TGTX
- TG Therapeutics says about 6-9 months behind U.S. on potential EU approval
- TG Therapeutics says Briumvi annual maintenance WAC price $59,000
- TG says ‘ideally’ Briumvi to be in centers within 30-45 days of new year
- TG Therapeutics doesn’t see need to raise additional capital at this time